Abstract Purpose: There is accumulating evidence that microRNAs may function like classic tumor suppressor genes but little is known about their mechanism of inactivation in cancer cells. We investigated whether somatic mutations are a common mechanism of inactivation of microRNA genes in ovarian cancer. Experimental Design: Ten cancer-implicated microRNA genes were analyzed for somatic mutations in 90 ovarian epithelial cancers and matching normal DNA. High-resolution melt analysis and bidirectional sequencing was used to detect sequence variations. Results: High-resolution melt analysis and direct sequencing did not identify any somatic mutations but did reveal numerous novel and previously reported germ line base substitutions, deletions, and insertions surrounding the mature microRNA sequences. The majority of variants were detected in the same proportion of non^cancer control individuals suggesting that they do not represent ovarian cancer^predisposing alleles.
Over the past decade, striking advances have been made in technologies that identify tumor-specific regions of genomic gain or loss. These aberrations are believed to be the hallmarks of important cancer-suppressing or cancer-promoting genes at those locations. To identify the responsible gene, many investigators have relied on identifying somatic activating or inactivating mutations, and more recently, epigenetic changes surrounding gene promoters. Although there have been successes, in many cases, the identity of the target gene has remained elusive. This outcome has presented a conundrum because in many instances there is strong evidence that such genomic aberrations should be reliable markers of cancer genes. Recently, a new paradigm in gene regulation has emerged which might explain, at least in part, the failure of past cancer gene mapping studies. Increasing evidences are emerging that microRNAs, which are small noncoding regulatory RNA products, are abnormally expressed in many cancer types (1) . The fact that a large proportion of microRNA genes are also located in genomic regions that are altered in cancer (2, 3) suggests that they may behave as classic tumor suppressor genes and oncogenes. If this is true, then one would expect microRNA genes to accumulate somatic mutations in the same manner as conventional cancer-promoting genes. However, very few studies have included microRNA genes in mutational analyses, so the extent to which micro-RNA genes are targeted as classic tumors suppressors is unclear (4 -7).
To gain a better understanding of the contribution to carcinogenesis of somatic mutation in microRNAs, we have investigated 10 key microRNA genes that have been implicated as having a tumor-suppressive role in one or more cancer types (Table 1; refs. 4, 8 -20) . These microRNAs were screened for somatic mutations that might affect the production of the mature transcript, including regions involved in the initiation of microRNA transcription and posttranscriptional processing. Ovarian cancers were studied as a model system because this is one of the cancer types in which extensive genomic alterations exist (21) but few of the target cancer genes have been identified.
Materials and Methods
Clinical samples and DNA extraction. Ovarian cancer biopsies were obtained from women undergoing surgery for primary ovarian cancer at hospitals in the south of England (22) . Tumor DNA was extracted from fresh-frozen tissue. Representative sections were H&E-stained and all tumors were assessed to contain >60% tumor epithelium. Normal DNA was extracted from matching peripheral blood samples, as described previously (23). In total, 90 ovarian malignancies were analyzed and comprised 42 serous, 21 endometrioid, 15 mucinous, 2 clear cell, and 10 undifferentiated tumors. The controls (n = 90) represent the population from which the ovarian cases arose and consisted of Caucasian female volunteers who were either staff at the Princess Anne Hospital, Southampton, UK or patients attending for nonneoplastic disease conditions. The control and cancer groups were drawn from the same geographic area, which has a predominantly Anglo-Saxon population (24) .
Appropriate institutional ethics committees approved the collection and use of tissues for this study, and ethics approval for this project was obtained from the Peter MacCallum Cancer Centre, where the molecular studies were carried out.
Detection of microRNA mutations. Primer pairs were designed to allow the analysis of two overlapping amplicons surrounding the mature microRNA sequence. Mutation detection was done using high-resolution melting analysis. PCR and melt profiling were done in a LightCycler480 (Roche Diagnostics) using a 96-well plate format. Reactions (10 AL total volume) were prepared as follows:
Amol/L of each deoxynucleotide triphosphate, 300 nmol/L of specific primers (Table 2) PCR was done at 94jC for 10 min, followed by 50 to 65 cycles of 94jC Â 30 s, 65jC Â 30 s, and 72jC Â 30s, at the end of which the temperature was raised to 94jC for 10 s followed by rapid cooling to 40jC.
Melt analysis was done using LightScanner software (Idaho Technology). Melting profiles were generated when the specific PCR amplicons were heated from 70jC to 97jC. Melting data was normalized, temperature shifted, and displayed as melting curves and subtractive difference plots.
Sequence analysis. Genomic DNA was amplified by PCR (primer sequences in Table 2 ) from those ovarian tumor biopsies in which a shift in melt profiles was detected, and was subjected to bidirectional sequencing using the BigDye terminator sequencing method (Applied Biosystems) on an autosequencer (ABI 3130, Applied Biosystems).
Results and Discussion
Ninety epithelial ovarian cancers were assessed for somatic mutations in an f500 bp genomic region surrounding each mature microRNA, which includes the binding sites for posttranscriptional processing by the RNases, Drosha and Dicer, as well as covering potential upstream regulatory sequences. Matching normal DNA was available for all tumors, which enabled us to determine whether the genetic variation detected was somatic or germ line. Despite analyzing a large cohort of primary tumors, no somatic mutations were detected in the genomic region corresponding to the primary, precursor, or mature microRNA in any of the 10 cancerimplicated microRNA genes studied. If somatic mutation were a common mechanism of inactivation/down-regulation of microRNAs, one might have expected to have observed at least 
Translational Relevance
MicroRNA expression is frequently altered in cancers, suggesting that they may represent a novel class of cancer-promoting gene. Classic tumor suppressor genes are frequently inactivated in cancer through somatic inactivating mutations but it is currently unclear if this is also true for tumor-suppressive microRNA genes. Understanding the molecular basis of aberrant microRNA expression in cancer will clearly affect the extent to which these genes can be used as clinically useful diagnostic or prognostic markers and/or novel therapeutic targets. In this study, we show that somatic mutations in microRNA genes are rare in ovarian cancers, and couple with data from other studies, it can be reasonably concluded that this is an uncommon mechanism of inactivation of microRNA genes in primary human cancers. (20, 25) . In addition, many of these microRNA genes are located in genomic regions frequently showing loss of heterozygosity in ovarian and other cancers (2, 3), adding further weight to the expectation that some of these genes should harbor somatic mutations. For example, within our sample set, loss of heterozygosity at the let-7a-3/let-7b and mir-143/mir-145 loci was detected in 50% and 22% of cases, respectively (data not shown). The absence of somatic mutations is unlikely to be due to the mutation detection method because high-resolution melting is emerging as one of the more robust and sensitive methods available (26) . In addition, we were able to detect many germ line base substitutions, deletions, and insertions in 5 ¶ and 3 ¶ sequences surrounding the precursor sequences (Table 3) . A summary of the sequence variants detected by us and others, and their location relative to the pre-microRNA and mature microRNA sequence, is presented in Fig. 1 .
Of the 10 microRNA genes investigated, let-7a-2, mir-145, and mir-200c did not harbor any detectable germ line variants in the cohort studied. Many of the variants detected are annotated single nucleotide polymorphisms, but three novel variations were identified in mir-10b and mir-143. We were also able to show that three potentially somatic variations previously observed in let-7b (delC-26 and G+29C) and mir-143 (G-91A) cancer cell lines (5) are in fact germ line polymorphisms. To assess if these rare sequence variants might represent predisposing alleles, their frequency was assessed in a matching number of non -cancer control individuals (Table 3) . Five of the six variants were detected in the controls at a similar frequency to the cancer cases, suggesting that these are rare nonpathogenic polymorphisms. However, it remains possible that they might represent low-penetrance cancer-predisposing alleles, but assessment of this would require analysis in a large case-control group which was beyond the scope of the current study.
Our data suggest that somatic mutation may not be a common mechanism of microRNA inactivation in ovarian cancer. Although it is possible that mutations might exist in other microRNA genes, those analyzed in this study included genes with an abundance of functional and/or gene expression data that strongly supports a tumor suppressor function. In fact, our data is consistent with the surprising rarity of somatic mutations in microRNAs reported in the literature. Among the three studies that have undertaken somatic mutation analysis in primary tumors (4, 6, 7) only two confirmed somatic mutations have been identified among more than 300 primary cancers. The largest single study investigated 336 microRNA genes in up to 172 primary colorectal, prostate, lung, and breast cancer and identified only a single somatic mutation in 1 of 72 prostate cancers (7). Although Wu et al. did not investigate all 336 microRNA genes in all of these tumors, when considered in the light of our data from 90 primary ovarian cancers, the evidence supports the view that somatic mutation may not be a common mechanism of inactivation of tumor-suppressive microRNAs. This conclusion is further supported by the observations that putative germ line mutations in microRNA precursors do not seem to have any effect on the production of mature microRNA in vivo (5, 6). Hypermethylation of CpG islands located in presumptive microRNA promoter regions has been reported (19, 27) and it is possible that this might explain the majority of the microRNA expression changes in cancer.
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No potential conflicts of interest were disclosed. Fig. 1 . A summary of variations detected in the genomic sequence surrounding candidate microRNA. Novel variations detected in this study (red), alterations observed here that have been reported in previous studies (4^7) or SNP databases (Ensemble Genome Browser, release 45; blue), and variations that were not detected in this study (gray). Genes are represented in the 5 ¶ to 3 ¶ orientation and the positions of the variations are reported with respect to the precursor microRNA molecule. No variations have been reported or detected in this study in mir-200c. *, these variations were detected in cell lines and therefore those not detected in this study might represent somatic mutations; c , reported as a somatic mutation in chronic lymphocytic leukemia (4) .
